Boundless Bio, Inc. Common Stock

Market Cap

$54M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.47+$1.25 (+102.46%)

Jul 15, 2026

52W High $2.6052W Low $1.05

Company Details

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed t...

Leadership

Zachary D. Hornby

CEO, President & Director

Christian Hassig Ph.D.

Chief Scientific Officer

Robert C. Doebele M.D., Ph.D.

Chief Medical Officer

David Hinkle

Senior VP of Finance, Controller & Corporate Treasurer

Jessica Oien J.D.

Chief Legal Officer & Corporate Secretary

Meredith Wesley

Chief Human Resources Officer

IPO Date

Mar 28, 2024

Website

boundlessbio.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$56M

EPS (Diluted)

Free Cash Flow

-$48M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee